ÌìÃÀ´«Ã½

ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
ÌìÃÀ´«Ã½ Access

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ ÌìÃÀ´«Ã½ Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

ÌìÃÀ´«Ã½ Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Citations : 4334

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • ÌìÃÀ´«Ã½ J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
Share This Page

Hepcidin quantification in Neurodegenerative diseases

8th International Conference on Dementia and Dementia Care

Manolov V, Hadjidekova S, Petrova J, Vasilev V, Petrova M, Kuntchev T, Jelev Y, Tzatchev K, Jeliazkov P and Traykov L

Medical University Sofia, Bulgaria

Posters & Accepted Abstracts: J Alzheimers Dis Parkinsonism

DOI:

Abstract
Aim: Neurodegenerative diseases are conditions in which the nervous system progressively and irreversibly deteriorates. Neurodegenerative diseases are often late manifestation of disorders typified by Alzheimer's disease (AD), Parkinson's disease (PD), Huntingtonâ��s disease (HD) and amyotrophic lateral sclerosis (ALS). AD depends on age, is chronic disease, a leading cause for dementia. Brain atrophy is main sign in AD cases. PD is another neurodegenerative disease, and also usually involves elder people. HD is characterized by abnormal involuntary writhing movements called chorea. We aimed to find a connection between iron homeostasis regulator hepcidin and neurodegenerative diseases patients. Materials and Methods: 17 patients with Huntingtonâ��s disease, 23 with Alzheimerâ��s and 19 with Parkinsonâ��s disease were included; 31 females (52.5%). They had clinical and neurological examination, EMG. They were evaluated for routine biochemical parameters, and additional serum hepcidin and glutathione peroxidase (GPX) were quantified. Hepcidin and GPX were evaluated by ELISA methods. The results obtained from HD, AD and PD patients were compared to age and gender matched healthy controls. Statistical analysis of established results was performed using Pearsonâ��s correlation and Studentâ��s paired t-test. Results: We found statistically significant elevated serum hepcidin levels in HD patients compared to healthy controls (51.6 �µg/L �± 10.2 �µg/L; 20.4 �µg/L �± 4.9 �µg/L; P<0.001). In AD and PD cases we found also increased serum hepcidin (61.4 �µg/L �± 12.3 �µg/L; and 54.9 �µg/L �± 5.7 �µg/L), compared to controls (P<0.001). GPX activity was decreased in HD patients compared to control group (7.8 pg/mL �± 1.9 pg/mL; 35.8 pg/mL �± 11.9 pg/mL; P<0.005). In AD and PD cases we found also decreased GPX levels (8.4 pg/mL �± 2.2 pg/mL; 8.9 pg/mL �± 1.4 pg/mL), compared to controls (P<0.05). Conclusion: Because of increased concentration of metals passing blood-brain barrier (BBB) in connectivity of neuronal medium with blood vessels. This makes the brain more likely to develop neurodegeneration. Serum hepcidin quantification might be a new biomarker for early HD, AD and PD diagnosis.
Biography
International Conferences 2025-26
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top